ModifiedMass General Brigham Health PlanPolicy N/A
Enzyme and Metabolic Disorder Therapies
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs MassHealth UPPL medical-benefit coverage, prior authorization, and quantity-limit requirements for enzyme and metabolic disorder therapies in members with specified lysosomal, metabolic, immune, or plasminogen disorders.
Policy Summary
PayerMass General Brigham Health Plan
PolicyEnzyme and Metabolic Disorder Therapies
Policy CodePolicy N/A
Change TypeModified
Effective DateJanuary 4, 2027
Last ReviewNov 4, 2026
Next Review DateN/A
Key ActionSubmit prior authorization with the applicable diagnosis, disease-confirming testing, specialist documentation, current weight, and drug-specific criteria.
Ryplazim was added with initial and reauthorization criteria.
Xenpozyme was added with initial and reauthorization criteria for non-central nervous system manifestations of acid sphingomyelinase deficiency in adults and pediatric patients.
Lamzede was added to the policy and requires prior authorization.
Drugs managed through the pharmacy benefit were removed from the policy while medical-benefit drugs remained.
Palynziq was removed from the policy and allowed to remain on the medical benefit in preparation for Prime implementation.
The policy was updated to include the expanded Cerezyme indication for type 1 and type 3 Gaucher disease.
Examples of positive response for Xenpozyme reauthorization were added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
19Therapies listed
RequiredPrior authorization
AppliesQuantity limit
MedicalBenefit channel
90 daysNew-member treatment lookback
General Coverage Criteria
General coverage pathway
Coverage may be authorized through either pathway below.
Coverage pathway
New plan member: The member has a coverage effective date of 90 days or less, is currently receiving the requested drug, and medical records documenting current treatment are submitted.
Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this pathway.
Drug-specific criteria: Authorization is requested under and meets all applicable drug-specific criteria.
Aldurazyme initial therapy
Aldurazyme is covered when all of the following are met.
Aldurazyme criteria
Diagnosis of mucopolysaccharidosis I (MPS I).
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Diagnostic confirmation
Genetic testing confirms mutations in the IDUA gene.
Enzyme assay confirms reduced lysosomal alpha-L-iduronidase activity in peripheral blood leukocytes, plasma, or cultured fibroblasts.
Current member weight is provided for dosing verification.
Cerezyme initial therapy
Cerezyme is covered when all of the following are met.
Cerezyme criteria
Diagnosis of Gaucher disease, Type I or Type 3.
Diagnostic confirmation
Genetic testing confirms a mutation in the GBA gene.
Genetic testing confirms full or partial loss of the LAL gene.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Lamzede initial therapy
Lamzede is covered when all of the following are met.
Lamzede criteria
Diagnosis of alpha-mannosidosis.
Member is at least 3 years of age.≥3 years
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Genetic testing confirms alpha-mannosidosis, such as a mutation in the MAN2B1 gene.
Baseline measurements
Lumizyme initial therapy
Lumizyme is covered when all of the following are met.
Lumizyme criteria
Diagnosis of Pompe disease.
Diagnostic confirmation
GAA assay shows reduced or absent activity from cultured skin fibroblasts.
Lymphocyte testing supports the diagnosis.
Blood spot assay supports the diagnosis.
Genetic testing confirms a mutation in the GAA gene.
Mepsevii initial therapy
Mepsevii is covered when all of the following are met.
Mepsevii criteria
Diagnosis of mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Genetic testing shows mutations in the beta-glucuronidase gene.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Naglazyme initial therapy
Naglazyme is covered when all of the following are met.
Naglazyme criteria
Diagnosis of mucopolysaccharidosis VI (MPS VI).
Enzyme assay shows reduced arylsulfatase B activity in leukocytes or fibroblasts and urine glycosaminoglycan levels are elevated.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Nexviazyme initial therapy
Nexviazyme is covered when all of the following are met.
Nexviazyme criteria
Diagnosis of late-onset Pompe disease.
Diagnostic confirmation
GAA assay shows reduced or absent activity from cultured skin fibroblasts.
Lymphocyte testing supports the diagnosis.
Blood spot assay supports the diagnosis.
Genetic testing confirms a mutation in the GAA gene.
Nulibry initial therapy
Nulibry is covered when all of the following are met.
Nulibry criteria
Diagnosis of molybdenum cofactor deficiency Type A confirmed by genetic testing.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Appropriate dosing is documented.
Current member weight is provided for dosing verification.
Revcovi initial therapy
Revcovi is covered when all of the following are met.
Revcovi criteria
Diagnosis of adenosine deaminase severe combined immunodeficiency (ADA-SCID).
Supporting laboratory or clinical evidence
Absent ADA enzymatic activity in lysed erythrocytes.
Elevated adenosine and deoxyadenosine in urine and plasma.
Markedly increased deoxyadenosine triphosphate (dATP) in erythrocyte lysates.
Significantly decreased ATP concentration in red blood cells.
Ryplazim initial therapy
Ryplazim is covered when all of the following are met.
Ryplazim criteria
Diagnosis of plasminogen deficiency type 1 (PLGD type 1).
History of external and/or internal lesions and symptoms consistent with PLGD type 1, such as ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress or obstruction, or abnormal wound healing.
Baseline plasminogen activity is 45% or less.≤45%
Laboratory evidence
Genetic testing shows mutations in the PLG gene.
Vimizim initial therapy
Vimizim is covered when all of the following are met.
Vimizim criteria
Diagnosis of mucopolysaccharidosis IVA (Morquio A syndrome).
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is documented for dosing verification.
Xenpozyme initial therapy
Xenpozyme is covered when all applicable criteria are met.
Xenpozyme criteria
Diagnosis of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) type B or type A/B.
Prescriber is a specialist familiar with lysosomal storage disorders, or specialist consultation notes are provided.
Age-specific disease severity
Members ≥18 years: DLco is 70% or less of predicted normal and spleen volume is at least 6 MN.DLco ≤70%; spleen volume ≥6 MN
Members <18 years:
Continuation therapy
Continuation therapy requires the drug-specific requirements below.
Drug-specific continuation requirements
Lamzede
Within the past 3 months, testing documents positive response in serum oligosaccharides, forced vital capacity, and one motor-function test: 3-minute stair climb or 6-minute walk.Testing within 3 months
Medical necessity for continued therapy is documented.
Ryplazim or Nulibry: A physician documents a positive response to therapy or provides clinical rationale for continued use; dosing is appropriate based on updated member weight where applicable.
Xenpozyme
Lumizyme and Nexviazyme must not be used concurrently. When Nexviazyme is requested, the member must meet its separate eligibility requirements, including a weight of <30 kg and a contraindication to Lumizyme.
Xenpozyme is not covered for members with acute or rapidly progressive neurologic abnormalities, those requiring invasive ventilatory support, or those requiring noninvasive ventilatory support while awake for more than 12 hours per day.
Clinical Thresholds and Utilization Parameters
Lamzede baseline motor function
Required baseline testingOne motor function test must be documented
Test option 13-minute stair climb test
Test option 26-minute walk test
Ryplazim baseline plasminogen activity
Baseline plasminogen activity≤45%
Applies toRyplazim initial therapy
Measurement timingBaseline
Authorization, Documentation, and Denial Risks
Prior Authorization
Prior Authorization Required
Prior authorization is required under the MassHealth Unified Preferred Pharmacy List (UPPL) for the listed enzyme and metabolic disorder therapies when requested under the medical benefit. The program includes quantity limits; submit requests through the applicable medical-benefit process.
Medical benefit prior authorization applies to Aldurazyme, Cerezyme, Elaprase, Elelyso, Elfabrio, Fabrazyme, Kanuma, Lamzede, Lumizyme, Mepsevii, Naglazyme, Nexviazyme, Nulibry, Revcovi, Ryplazim, Vimizim, Vpriv, and Xenpozyme.
Elfabrio, Fabrazyme, Revcovi, and Ryplazim may also be available through the pharmacy benefit; consult the MassHealth Drug List for pharmacy-benefit coverage and criteria.
Prior Authorization
Lamzede Prior Authorization
Lamzede requires medical-benefit prior authorization before coverage. Submit documentation supporting the diagnosis, specialist involvement, required testing, baseline measurements, age, and dosing.
Medical-benefit prior authorization is required for velmanase alfa-tycv (Lamzede).
Disease and Treatment Background
Lysosomal storage disorders result from a deficiency or absence of enzymes needed to degrade specific compounds. The resulting accumulation of these compounds can cause cellular and organ dysfunction. Enzyme replacement therapy (ERT) supplies exogenous enzymes to replace deficient enzymes and is used for conditions including Gaucher disease, Fabry disease, mucopolysaccharidosis types I, II, and VI, and Pompe disease.
Policy Definitions
Enzyme replacement therapy
TermEnzyme replacement therapy (ERT)
DefinitionExogenously supplied enzymes used to replace deficient enzymes
Clinical contextUsed in lysosomal storage disorders
PLGD type 1
AbbreviationPLGD type 1
Full termPlasminogen deficiency type 1
Associated therapyRyplazim
Agent-Specific Initial Therapy
Aldurazyme initial therapy
Aldurazyme is covered when all of the following are met.
ALL of the following
Diagnosis of mucopolysaccharidosis I (MPS I).
Genetic or metabolic disease specialist prescriber or specialist consultation.
ANY of the following
IDUA mutation testing confirms the diagnosis.
Reduced lysosomal alpha-L-iduronidase activity is demonstrated in peripheral blood leukocytes, plasma, or cultured fibroblasts.
Lamzede: Within the past 3 months, testing documents positive response in serum oligosaccharides, forced vital capacity, and one motor-function test, plus medical necessity for continued treatment.
Ryplazim or Nulibry: Physician documents positive response or clinical rationale for continued use; dosing is appropriate based on updated weight where applicable.
Xenpozyme: Documentation shows improvement from baseline in DLco, spleen volume, liver volume, platelet count, or pediatric height Z-scores, and updated member weight is provided.
Dose and Quantity Limits
Ryplazim quantity limit
Maximum dose per administration≤6.6 mg/kg
Dosing frequencyEvery two to four days
Quantity-limit drugRyplazim
Policy Summary
PayerMass General Brigham Health Plan
PolicyEnzyme and Metabolic Disorder Therapies
Policy CodePolicy N/A
Change TypeModified
Effective DateJanuary 4, 2027
Last ReviewNov 4, 2026
Next Review DateN/A
Key ActionSubmit prior authorization with the applicable diagnosis, disease-confirming testing, specialist documentation, current weight, and drug-specific criteria.
Current member weight is provided for dosing verification.
Elfabrio only: There is an inadequate response, adverse reaction, or contraindication to Fabrazyme.
Baseline serum oligosaccharides are documented.
Baseline forced vital capacity is documented.
Motor function test
Baseline 3-minute stair climb test is documented.
Baseline 6-minute walk test is documented.
Current member weight is provided for dosing verification.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Member is at least 1 year of age.≥1 year
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Member weighs less than 30 kg and has a contraindication to Lumizyme.<30 kg
Absent or extremely low N adenosylhomocysteine hydrolase in red blood cells.
Severe T-cell deficiency manifested by lymphopenia and poor T-cell responses to mitogens and antigens.
Absent thymic shadow on chest radiograph.
Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
Current member weight is provided for dosing verification.
Plasminogen antigen level is 9 mg/dL or less.≤9 mg/dL
Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
Spleen volume is at least 5 MN.
≥5 MN
Member does not have acute or rapidly progressive neurologic abnormalities.
Member does not require invasive ventilatory support and does not require noninvasive ventilatory support while awake for more than 12 hours a day.Awake noninvasive support ≤12 hours/day
Current member weight is provided for dosing verification.
Appropriate dosing is documented.
Documentation shows improvement from baseline in DLco, spleen volume, liver volume, platelet count, or height Z-scores in children.
Updated member weight is provided.
All other drugs: Prescriber resubmission infers a positive response to therapy.
Ryplazim plasminogen antigen
Plasminogen antigen threshold≤9 mg/dL
Evidence pathwayAlternative to PLG gene mutation testing
Applies toRyplazim
Ryplazim requested dose
Maximum dose≤6.6 mg/kg
FrequencyEvery two to four days
Applies toRyplazim requested dose
Nexviazyme age
Minimum age≥1 year
TherapyNexviazyme
Disease indicationLate-onset Pompe disease
Nexviazyme weight restriction
Maximum eligible weight<30 kg
Additional requirementContraindication to Lumizyme
Concurrent useLumizyme and Nexviazyme should not be used concurrently
Elelyso age
Minimum age≥4 years
TherapyElelyso
IndicationGaucher disease Type I
Lamzede age
Minimum age≥3 years
TherapyLamzede
IndicationAlpha-mannosidosis
Vimizim age
Minimum age≥5 years
TherapyVimizim
IndicationMucopolysaccharidosis IVA (Morquio A syndrome)
Baseline plasminogen activity
Baseline plasminogen activity≤45%
Required forRyplazim eligibility
Measurement pointBaseline
Ryplazim dose
Dose limit≤6.6 mg/kg
Dosing frequencyEvery two to four days
DrugRyplazim
Plasminogen antigen level
Antigen threshold≤9 mg/dL
Testing evidencePlasminogen antigen level
Alternative evidencePLG gene mutations on genetic testing
Adult Xenpozyme DLco
Adult age groupMembers ≥18 years of age
DLco threshold≤70% of predicted normal value
Required with DLcoSpleen volume ≥6 MN
Adult Xenpozyme spleen volume
Adult spleen-volume threshold≥6 MN
Adult age groupMembers ≥18 years of age
Required with spleen volumeDLco ≤70% of predicted normal value
Pediatric Xenpozyme spleen volume
Pediatric spleen-volume threshold≥5 MN
Pediatric age groupMembers <18 years of age
TherapyXenpozyme
Awake noninvasive ventilatory support
Daily-use restrictionMust not be required for more than 12 hours a day
Support typeNoninvasive ventilatory support while awake
TherapyXenpozyme
Use the medical-benefit contact process for requests; pharmacy-benefit coverage and criteria may differ.
Documentation Required
Document Current Treatment for New Members
For a member who has been covered by the plan for 90 days or less, submit medical records showing that the member is currently receiving the requested drug. Do not rely on treatment obtained only through samples or a manufacturer patient-assistance program.
The coverage-effective date must be less than or equal to 90 days before the request.
Records should document current treatment with the requested product and should exclude treatment obtained as samples or through manufacturer patient assistance.
Documentation Required
Submit Complete Clinical Documentation
Submit records that establish the drug-specific diagnosis, required genetic or enzyme testing, specialist prescribing or consultation, current weight for dose verification, and any product-specific age, baseline-measurement, dose, or clinical requirements.
Aldurazyme: MPS I; IDUA mutation or reduced alpha-L-iduronidase activity; genetics/metabolic specialist; current weight.
Cerezyme: Type I or Type 3 Gaucher disease; GBA mutation or reduced glucocerebrosidase activity; genetics/metabolic specialist; current weight.
Elelyso and Vpriv: Type I Gaucher disease; GBA mutation or reduced glucocerebrosidase activity; specialist; current weight. Elelyso also requires age ≥4 years.
Fabrazyme: Fabry disease; reduced or absent α-GAL activity, GAL mutation, or elevated Gb3/GL-3 biomarker; specialist; current weight.
Kanuma: lysosomal acid lipase deficiency; low LAL activity or full/partial LAL-gene loss; specialist; current weight.
Lamzede: alpha-mannosidosis; age ≥3 years; specialist; MAN2B1 or other confirmatory genetic testing; baseline serum oligosaccharides, forced vital capacity, and either the 3-minute stair-climb or 6-minute walk test; current weight.
Lumizyme: Pompe disease; reduced/absent GAA activity by fibroblast, lymphocyte, or blood-spot testing, or GAA mutation; specialist; current weight.
Mepsevii: MPS VII/Sly syndrome; beta-glucuronidase-gene mutations; specialist; current weight.
Naglazyme: MPS VI; reduced arylsulfatase B activity with elevated urine GAG levels; specialist; current weight.
Nexviazyme: late-onset Pompe disease; qualifying GAA assay, lymphocyte, blood-spot, or GAA genetic testing; age ≥1 year; specialist; current weight; weight <30 kg and contraindication to Lumizyme.
Nulibry: genetically confirmed MoCD type A; specialist; appropriate dosing and current weight.
Revcovi: ADA-SCID; qualifying laboratory evidence such as absent ADA activity, elevated adenosine/deoxyadenosine, increased dATP, reduced RBC ATP, absent or very low erythrocyte SAH hydrolase, severe T-cell deficiency, or absent thymic shadow; specialist; current weight.
Ryplazim: PLGD type 1; compatible lesions and symptoms; baseline plasminogen activity ≤45%; PLG mutation or plasminogen antigen ≤9 mg/dL; dose ≤6.6 mg/kg every 2–4 days.
Vimizim: MPS IVA/Morquio A; age ≥5 years; reduced N-acetylgalactosamine-6-sulfatase activity in blood or skin cells; specialist; current weight.
Xenpozyme: non-CNS ASMD type B or A/B; specialist; required DLco/spleen-volume measurements by age; no acute or rapidly progressive neurologic abnormalities; no prohibited ventilatory support; current weight and appropriate dosing.
Documentation Required
Ryplazim Diagnostic Testing
For Ryplazim, document the diagnostic evidence for plasminogen deficiency type 1 and the clinical manifestations supporting treatment.
Provide genetic testing showing mutations in the PLG gene or plasminogen antigen levels ≤9 mg/dL.
Document a history of external or internal lesions and compatible symptoms, such as ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress or obstruction, or abnormal wound healing.
Submit baseline plasminogen activity ≤45% and confirm the requested dose is ≤6.6 mg/kg every two to four days.
Documentation Required
Vimizim Testing and Weight
For Vimizim, submit enzyme-assay evidence of reduced N-acetylgalactosamine-6-sulfatase activity and the member’s current weight for dose verification.
Document MPS IVA (Morquio A syndrome).
Member must be ≥5 years of age.
Provide testing from blood and/or skin cells, specialist involvement or consultation notes, and current weight.
Unsupported block type: documentation
Documentation Required
Lamzede Continuation Documentation
For Lamzede reauthorization, submit recent objective evidence of benefit and the medical necessity for continued treatment.
Provide testing from within the past 3 months showing a positive response in serum oligosaccharides, forced vital capacity, and either the 3-minute stair-climb or 6-minute walk test.
Document medical necessity for continuation, such as disease stabilization or reduction in expected motor decline.
Documentation Required
Xenpozyme Continuation Documentation
For Xenpozyme reauthorization, submit updated clinical evidence demonstrating benefit from baseline and the member’s current weight.
Document improvement from baseline in DLco, spleen volume, liver volume, platelet count, or height Z-scores for children.
Provide updated member weight to support dose verification.
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: step_therapy
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
ADA-SCID
AbbreviationADA-SCID
Full termAdenosine deaminase severe combined immunodeficiency
Associated therapyRevcovi
Current member weight is provided for dosing verification.
Cerezyme initial therapy
Cerezyme is covered when all of the following are met.
ALL of the following
Diagnosis of Gaucher disease, Type I or Type 3.
ANY of the following
GBA mutation is confirmed by genetic testing.
Reduced glucocerebrosidase activity is demonstrated by enzyme assay.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Elaprase initial therapy
Elaprase is covered when all of the following are met.
ALL of the following
Diagnosis of Hunter syndrome (MPS II).
ANY of the following
IDS mutation is confirmed by genetic testing.
Iduronate-2-sulfatase activity is reduced or absent in serum, white blood cells, or fibroblasts.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Member weight is used to verify appropriate dosing.
Elelyso and Vpriv initial therapy
Elelyso and Vpriv are covered when all of the following are met.
ALL of the following
Diagnosis of Gaucher disease, Type I.
ANY of the following
GBA mutation is confirmed by genetic testing.
Reduced glucocerebrosidase activity is demonstrated by enzyme assay.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
For Elelyso, member is at least 4 years old.≥4 years
Fabrazyme and Elfabrio initial therapy
Fabrazyme and Elfabrio are covered when all applicable criteria are met.
ALL of the following
Diagnosis of Fabry disease.
ANY of the following
Reduced or absent alpha-GAL activity is shown by enzyme assay.
GAL gene mutation is confirmed by genetic testing.
Gb3 or GL-3 concentration is increased.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
For Elfabrio, there is inadequate response, adverse reaction, or contraindication to Fabrazyme.
Kanuma initial therapy
Kanuma is covered when all of the following are met.
ALL of the following
Diagnosis of lysosomal acid lipase deficiency.
ANY of the following
Low lysosomal acid lipase activity is documented by laboratory assay.
Full or partial loss of the LAL gene is confirmed by genetic testing.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Lamzede initial therapy
Lamzede is covered when all of the following are met.
ALL of the following
Diagnosis of alpha-mannosidosis.
Member is at least 3 years old.≥3 years
Genetic or metabolic disease specialist prescriber or specialist consultation.
Genetic testing confirms alpha-mannosidosis.
Baseline serum oligosaccharides, forced vital capacity, and one motor-function test are documented.
Current member weight is provided for dosing verification.
Lumizyme initial therapy
Lumizyme is covered when all of the following are met.
ALL of the following
Diagnosis of Pompe disease.
ANY of the following
Qualifying GAA enzyme assay, lymphocyte testing, or blood spot assay supports the diagnosis.
Genetic testing confirms a GAA mutation.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Mepsevii initial therapy
Mepsevii is covered when all of the following are met.
ALL of the following
Diagnosis of MPS VII (Sly syndrome).
Beta-glucuronidase gene mutations are demonstrated by genetic testing.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Naglazyme initial therapy
Naglazyme is covered when all of the following are met.
ALL of the following
Diagnosis of MPS VI.
Reduced arylsulfatase B activity and elevated urine glycosaminoglycan levels are documented.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Nexviazyme initial therapy
Nexviazyme is covered when all of the following are met.
ALL of the following
Diagnosis of late-onset Pompe disease.
ANY of the following
Qualifying GAA enzyme assay, lymphocyte testing, or blood spot assay supports the diagnosis.
Genetic testing confirms a GAA mutation.
Member is at least 1 year old.≥1 year
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Weight is less than 30 kg and there is a contraindication to Lumizyme.<30 kg
Nulibry initial therapy
Nulibry is covered when all of the following are met.
ALL of the following
Genetically confirmed molybdenum cofactor deficiency Type A.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Appropriate dosing is documented.
Current member weight is provided for dosing verification.
Revcovi initial therapy
Revcovi is covered when all of the following are met.
ALL of the following
Diagnosis of ADA-SCID.
Qualifying evidence: At least one listed ADA, adenosine/deoxyadenosine, dATP, ATP, N adenosylhomocysteine hydrolase, T-cell deficiency, or chest-radiograph finding is documented.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is provided for dosing verification.
Ryplazim initial therapy
Ryplazim is covered when all of the following are met.
ALL of the following
PLGD type 1 with compatible lesion and symptom history.
Baseline plasminogen activity is 45% or less.≤45%
ANY of the following
PLG mutation is demonstrated by genetic testing.
Plasminogen antigen is 9 mg/dL or less.≤9 mg/dL
Dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
Vimizim initial therapy
Vimizim is covered when all of the following are met.
ALL of the following
MPS IVA (Morquio A syndrome).
Member is at least 5 years old.≥5 years
Reduced N-acetylgalactosamine-6-sulfatase activity is demonstrated by enzyme assay in blood or skin cells.
Genetic or metabolic disease specialist prescriber or specialist consultation.
Current member weight is documented for dosing verification.
Ryplazim initial therapy — genetic or antigen-level laboratory evidence
Ryplazim initial therapy requires all of the following.
ALL of the following
PLGD type 1 diagnosis with compatible lesions and symptoms.
Baseline plasminogen activity is 45% or less.≤45%
Laboratory evidence
PLG gene mutations are demonstrated by genetic testing.
Plasminogen antigen is 9 mg/dL or less.≤9 mg/dL
Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
Vimizim initial therapy — all listed criteria
Vimizim initial therapy requires all of the following.